The quality of drug small molecule crystallization directly determines the purity, stability, and bioavailability of the drug. The crystallization workstation, with the advantages of automated precise temperature control and multi-channel parallel screening, has become the core equipment for drug crystallization research and development. The scientific setting of solvent system ratio, cooling rate, stirring intensity and other parameters is the key to achieving "high-purity, large particle, uniform morphology" crystalline products. Combining the principles of crystallization thermodynamics and kinetics, we will break down the techniques for setting various parameters to provide efficient guidance for drug development.

The solvent system ratio is the basis of crystallization screening, and the core lies in "solubility difference regulation" and "precise control of supersaturation". According to the polarity characteristics of small drug molecules, a binary or multivariate system design of "good solvent+anti solvent" should be adopted: for small molecules with strong polarity (such as hydroxyl and carboxyl structures), good solvents should be preferred, such as water and methanol, while anti solvents should be combined with weakly polar solvents such as ethyl acetate and petroleum ether; Non polar small molecules use dichloromethane and toluene as good solvents, and n-hexane as an anti solvent. In terms of proportioning techniques, the principle of "gradient exploration+solubility curve reference" is followed. Firstly, solubility curves at different temperatures are drawn through pre experiments to determine the saturation concentration of the drug in a good solvent. Then, the anti solvent ratio is adjusted according to a gradient of 1:1 to 1:10. The initial anti solvent addition is controlled within 20% of the total system volume to avoid a sudden increase in supersaturation leading to microcrystalline agglomeration. For difficult to crystallize small molecules, co solvents (such as DMSO) can be introduced to enhance solubility, but the dosage should be ≤ 5% to prevent affecting the purity of crystallization.

The cooling rate directly affects the nucleation and growth process of crystals, and needs to be combined with the "gradient regulation" of drug crystallization characteristics. The precise temperature control function of the crystallization workstation provides a guarantee for rate optimization, and the core technique is "slow first and then fast" or "segmented cooling": for small molecules that are prone to forming supersaturated solutions, the initial cooling rate is controlled at 0.5-1 ℃/h, and maintained for 2-4 hours in the near saturation temperature range (usually 5-10 ℃ lower than the saturation temperature) to promote uniform generation of crystal nuclei; When a large number of small crystal nuclei appear in the system, increase the cooling rate to 2-5 ℃/h to accelerate crystal growth. For small molecules with slow crystallization kinetics, a "low-temperature induction+slow heating" strategy should be adopted: first, the system should be rapidly reduced to 0-5 ℃ to induce nucleation, and then slowly heated at a rate of 0.2 ℃/h to dissolve small crystal nuclei and grow large ones, thereby improving crystal uniformity. Special attention should be paid to the cooling endpoint temperature, which should be at least 5 ℃ higher than the solidification point of the solvent, to avoid freezing and damaging the crystalline morphology of the system.

The setting of stirring intensity should balance "mass transfer efficiency" and "crystal integrity" to avoid excessive stirring leading to crystal breakage. The multi-channel stirring module of the crystallization workstation can achieve independent parameter adjustment, following the principle of "three-stage stirring" in terms of technique: the solvent mixing stage uses high speed (200-300rpm) to ensure uniform mixing of good solvent and anti solvent, allowing small drug molecules to dissolve quickly; Reduce the cooling crystallization stage to a medium speed (100-150rpm), promote solute diffusion to the surface of the crystal nucleus through gentle stirring, accelerate crystal growth, and prevent crystal settling and accumulation; Reduce the speed to low (50-80rpm) in the later stage of crystallization to reduce collision and friction between crystals and protect the integrity of crystal morphology. For solvent systems with high viscosity, it is necessary to increase the stirring speed appropriately, but not exceeding 350rpm at most. This can be combined with blade type optimization (such as anchor blades replacing propeller blades) to enhance the mixing effect of the system.

In addition, parameter collaborative optimization cannot be ignored: when the proportion of anti solvent in the solvent system is high, the cooling rate and stirring intensity need to be reduced to avoid losing control of supersaturation; For high viscosity systems, the stirring speed should be increased while slowing down the cooling rate to balance mass transfer and crystallization processes. The real-time monitoring function of the crystallization workstation can assist in parameter adjustment. The crystal growth status can be observed through an online particle size analyzer. If there are too many microcrystals, the cooling rate will be reduced. If the crystal size is uneven, the stirring intensity will be optimized.

The core parameter setting for drug small molecule crystallization screening is "thermodynamic adaptation+kinetic regulation". The solvent ratio determines the possibility of crystallization, while the cooling and stirring parameters determine the quality of crystallization. Suggest utilizing the automated screening function of the crystallization workstation to design a multi factor orthogonal experiment and quickly lock in parameter combinations.